Utility of circulating tumour DNA (ctDNA) in place of FFPE
Research type
Research Study
Full title
A service evaluation study to determine the utility of using circulating tumour DNA (ctDNA) as an alternative sample to generate genomic results.
IRAS ID
344031
Contact name
James Beasley
Contact email
Sponsor organisation
Birmingham Women's and Children's NHS Trust
Duration of Study in the UK
1 years, 0 months, 1 days
Research summary
We're investigating a new method to analyze cancer patients' genetic information. Instead of traditional tissue biopsies, we're looking at a small amount of DNA found in the blood called ctDNA. This study aims to see if ctDNA can give us the same valuable information as tissue biopsies for guiding targeted cancer treatments.
We won't be collecting any new data beyond what's already gathered in standard of care. We'll simply be using a different source of genetic material. Patients won't receive any new treatments based on these results, and the findings won't be shared with them directly. Instead, we'll use the data to improve how we deliver cancer care in the future.
Participation involves providing an extra blood sample during routine treatment, with the consent of the treating oncologist. This study is important for advancing how we understand and treat cancer, potentially offering less invasive methods for monitoring the disease and guiding treatment decisions.
REC name
East of England - Essex Research Ethics Committee
REC reference
25/EE/0098
Date of REC Opinion
9 Jun 2025
REC opinion
Further Information Favourable Opinion